Sanofi India Ltd (SANOFI)
₹3,122.00
Mkt cap
₹7,273 Cr
P/E ratio
21.20
P/B
8.70
Div yield
2.37%
ROE
43.00%
ROCE
57.50%
EPS (TTM)
₹147.26
Book value
₹359
52W range
3,097–5,130
Sector
Healthcare
Price history
Previous close
Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines. [1]
NSE SANOFIBSE 500674
Health check
Mixed
ValuationCheap
ProfitabilityStrong
GrowthLow
TechnicalsBearish
52-week range
−39.14% from high₹3,122
₹3,097+0.80% from low₹5,130
Current
₹3,122.00
Prev close
₹3,158.20
Day
−1.15%
Price performance
1D
−1.21%
1W
−0.13%
1M
−6.85%
3M
−1.01%
6M
−18.43%
1Y
−38.96%
YTD
−24.62%
Financials
Revenue, profit & margin
P/E ratio
21.2×
SANOFI is 38% below the sector median of 34.0×
SANOFI21.2×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 515 | 491 | 469 | 511 | 464 | 524 | 515 | 536 | 406 | 475 | 420 | 472 | 438 | |
| Expenses | 393 | 377 | 370 | 374 | 348 | 404 | 397 | 364 | 311 | 341 | 330 | 330 | 322 | |
| Operating Profit | 122 | 114 | 100 | 137 | 116 | 120 | 118 | 172 | 95 | 134 | 90 | 143 | 115 | |
| OPM % | 24% | 23% | 21% | 27% | 25% | 23% | 23% | 32% | 23% | 28% | 22% | 30% | 26% | |
| Other Income | 57 | 82 | 77 | 41 | 21 | 2 | 14 | 3 | 9 | -22 | 3 | 4 | 6 | |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 9 | 9 | 10 | 9 | 9 | |
| Profit before tax | 169 | 186 | 167 | 169 | 127 | 113 | 122 | 165 | 94 | 102 | 83 | 138 | 112 | |
| Tax % | 27% | 18% | 18% | 19% | 19% | 27% | 25% | 28% | 26% | 26% | 26% | 26% | 26% | |
| Net Profit | 123 | 152 | 138 | 137 | 103 | 82 | 91 | 120 | 70 | 76 | 62 | 103 | 84 | |
| EPS in Rs | 53.43 | 66.17 | 59.87 | 59.39 | 44.96 | 35.74 | 39.70 | 51.96 | 30.22 | 33.04 | 26.83 | 44.61 | 36.30 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −1.94% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 4 Aug '26◦ |
| Earnings day | −1.94% |
| +1 day | −1.23% |
| +5 days | −4.44% |
| +15 days | −5.98% |
| +30 days | — |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202660.40%Promoter
Promoters60.40%
FIIs5.69%0.04
DIIs19.87%1.25
Public14.05%1.21
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| SANOFI | ₹3,158.20 | 21.22 | 7,273 | 2.37% | 84 | +20.14% | 438 | +7.73% | 57.51% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2013nseAnnual Report 2012bse
Concall transcripts19
Announcements5
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Receipt Of Show Cause Notice From GST Authorities 31 Aug - Sanofi India received GST show cause notice for FY21, with Rs 36.39 crore tax and penalty each.Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 13 Aug - Goa GST authority sanctioned ₹1.33 crore refund and dropped ₹75.63 lakh demand on 12 August 2026.Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 11 Aug - Income tax demand of Rs. 72.7 lakh for AY 2019-20 vacated following CIT(A) relief.Announcement under Regulation 30 (LODR)-Earnings Call Transcript 10 AugAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 6 Aug - Video recording of 5 August 2026 investor call on Q1 and half-year 2026 results uploaded.